naloxone

EC 207-365-7

Also known as N-allylnoroxymorphone.

Latest news on naloxone

16 October 2026
CHMP October 2026 meeting: approvals, indication changes and withdrawals

Approvals include Rasonque for metastatic pancreatic cancer, Foundayo oral GLP‑1 for weight and type 2 diabetes, Yuviwel for achondroplasia, two biosimilars and temozolomide for gliomas.